Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Vieito

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|December 21, 2025
Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy responseDaniel Navarro-Garcia, Francesco Grussu, Christina Zatse, et al.
Radiology. Artificial Intelligence|April 24, 2024
Erratum for: Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in CancerOlivia Prior, Carlos Macarro, Víctor Navarro, et al.
Radiology. Artificial Intelligence|January 31, 2024
Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in CancerOlivia Prior, Carlos Macarro, Víctor Navarro, et al.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Neuro-Oncology|May 31, 2022
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trialMacarena I de la Fuente, Howard Colman, Mark Rosenthal, et al.
JTO Clinical and Research Reports|October 1, 2025
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5Anas Gazzah, Charles Ricordel, Antoine Italiano, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsRavit Geva, Maria Vieito, Jorge Ramon, et al.
Nature Communications|March 14, 2023
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomasVictor Moreno, Maria Vieito, Juan Manuel Sepulveda, et al.
Clinical and Translational Science|June 20, 2024
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b studyJoaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2023
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid TumorsMaria Vieito, Victor Moreno, Anna Spreafico, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|December 21, 2025
Integrating C-reactive protein flare and early MRI dynamics for enhanced prediction of immunotherapy responseDaniel Navarro-Garcia, Francesco Grussu, Christina Zatse, et al.
Radiology. Artificial Intelligence|April 24, 2024
Erratum for: Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in CancerOlivia Prior, Carlos Macarro, Víctor Navarro, et al.
Radiology. Artificial Intelligence|January 31, 2024
Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in CancerOlivia Prior, Carlos Macarro, Víctor Navarro, et al.
Journal for Immunotherapy of Cancer|October 31, 2022
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumorsElizabeth J Davis, Juan Martin-Liberal, Rebecca Kristeleit, et al.
Neuro-Oncology|May 31, 2022
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trialMacarena I de la Fuente, Howard Colman, Mark Rosenthal, et al.
JTO Clinical and Research Reports|October 1, 2025
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5Anas Gazzah, Charles Ricordel, Antoine Italiano, et al.
Cancer Immunology, Immunotherapy : CII|August 6, 2024
Safety and clinical activity of JNJ-78306358, a human leukocyte antigen-G (HLA-G) x CD3 bispecific antibody, for the treatment of advanced stage solid tumorsRavit Geva, Maria Vieito, Jorge Ramon, et al.
Nature Communications|March 14, 2023
BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomasVictor Moreno, Maria Vieito, Juan Manuel Sepulveda, et al.
Clinical and Translational Science|June 20, 2024
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b studyJoaquina C Baranda, Debbie Robbrecht, Ryan Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2023
Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid TumorsMaria Vieito, Victor Moreno, Anna Spreafico, et al.
Pageof 4